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The carcinogenicity of arsenic in humans has
been unambiguously demonstrated in a variety
of epidemiologic studies (Pott et al. 2001).
Inorganic arsenic exposure has been associated
with cancers of the skin, lung, liver, kidney,
and urinary bladder [National Toxicology
Program (NTP) 2000]. Although arsenic car-
cinogenesis has many other targets, a signiﬁ-
cant association has also been observed
between prostate cancer and chronic arsenic
exposure (Chen and Wang 1990; Lewis et al.
1999). Arsenic can cause malignant transfor-
mation of human prostate epithelial cells
in vitro, and these CAsE-PE (chronic-arsenic–
exposed prostate epithelial) cells produce
aggressive, carcinoma-like tumors when inocu-
lated into nude mice (Achanzar et al. 2002).
There is also evidence that arsenic can enhance
tumor progression. For instance, oral exposure
to arsenic in mice not only increases the inci-
dence but also greatly increases the progression
of skin cancers associated with ultraviolet irra-
diation (Rossman et al. 2004). Furthermore,
transplacental exposure to arsenic is an effec-
tive carcinogen in mice, resulting in malignant
tumors of the liver and lung (Waalkes et al.
2004). In this model system, arsenic also
appears to act as a tumor progressor because it
greatly increases malignant liver tumor
multiplicity (Waalkes et al. 2004). Although
arsenic exposure is associated with prostate
cancer in humans (Chen and Wang, 1990;
Lewis et al. 1999), the role of arsenic in
prostate cancer progression is undeﬁned.
Prostate cancer is the second leading cause
of cancer death in American men (Crawford
2003). The normal prostate gland requires
androgen for growth and maintenance of dif-
ferentiated function and will undergo regres-
sion if androgen is withdrawn (Kyprianou and
Isaacs 1988). Prostate cancer therapy often
involves orchiectomy and pharmacologic inter-
vention to diminishing availability of androgen
at the androgen receptor (AR) within prostate
cancer cells. However, prostate cancer cells
often lose the need for androgen as a survival,
growth, or differentiation factor and become
androgen independent (Westin and Bergh
1998). Although poorly understood, this pro-
gression to androgen independence is clearly a
critical step in the development of advanced
prostate cancer (Suzuki et al. 2003). Androgen-
independent prostate cancers are typically more
advanced and difﬁcult to treat, and acquisition
of such independence has been called a “death
sentence” for prostate cancer patients (Arnold
and Isaacs 2002).
Altered AR levels or activity can be key ele-
ments in acquired androgen independence in
prostate cancer. AR is a nuclear transcription
factor that normally binds androgen to activate
its signaling pathway. Prostate cancer cells can
achieve functional AR signaling in the presence
of greatly diminished androgens in a variety of
ways (Deutsch et al. 2004). AR gene ampliﬁca-
tion and overexpression can make cells hyper-
sensitive to low levels of androgen, and many
prostate cancers show overexpression of AR
(Taplin and Balk 2004; Visakorpi et al. 1995).
In addition, AR mutations have been recog-
nized that change the ligand speciﬁcity of AR
such that it can be activated by nonandrogens
and even antiandrogens (Deutsch et al. 2004;
Tilley et al. 1996). Furthermore, ligand-inde-
pendent activation of the AR pathway appears
to occur in some instances, creating, in essence,
a bypass of AR (Feldman and Feldman 2001;
Gleave et al. 1999). For instance, certain
growth factors, such as insulin-like growth
factor-1, keratinocyte growth factor, and epi-
dermal growth factor (EGF), as well as HER2/
neu, a member of the EGF-receptor family of
receptor tyrosine kinase, can activate AR-
dependent genes in absence of AR ligand
(Culig et al. 1994; Yeh et al. 1999). Thus,
evidence suggests that altered AR levels, activ-
ity, or function can play a major role in the
development of androgen-refractory prostate
cancer cells (Deutsch et al. 2004; Zegarra-
Moro et al. 2002), although an AR bypass
can also be important (Culig et al. 1994; Yeh
et al. 1999). In men the primary circulating
androgen is testosterone. In the prostate,
testosterone is converted to the more potent
androgen 5-α-dihydrotestosterone (DHT) by
the enzyme 5α-reductase (5α-R) (Bonkhoff
et al. 1996). DHT is 3–10 times more potent
than testosterone in activating AR-regulated
downstream events (Martin and Coffey 1998).
There is evidence that a signiﬁcant portion of
human prostate cancers overexpress 5α-R
type 1 (Thomas et al. 2003). Androgens may
be converted to estrogens by the enzyme
5α-aromatase (5α-A) (Simpson et al. 1999).
Address correspondence to M.P. Waalkes, Inorganic
Carcinogenesis Section, NCI at NIEHS, P.O. Box
12233, Mail Drop F0-09, 111 Alexander Dr.,
Research Triangle Park, NC 27709 USA. Telephone:
(919) 541-2328. Fax: (919) 541-3970. E-mail:
waalkes@niehs.nih.gov
We thank L. Keefer, J. Liu, and W. Qu for their
critical review of the manuscript.
The authors declare they have no competing
ﬁnancial interests.
Received 7 December 2004; accepted 5 May 2005.
Acquisition of Androgen Independence by Human Prostate Epithelial Cells
during Arsenic-Induced Malignant Transformation
Lamia Benbrahim-Tallaa,1 Mukta M. Webber,2,3 and Michael P. Waalkes1
1Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at the National Institute of
Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North
Carolina, USA; 2Department of Medicine, and 3Department of Zoology, Michigan State University, East Lansing, Michigan, USA
Lethal phenotypes of human prostate cancer are characterized by progression to androgen
independence, although the mechanisms behind this progression remain unclear. Arsenic is a poten-
tial human prostate carcinogen that may affect tumor progression. In this study, we used a prostate
cancer cell model in which an immortalized, nontumorigenic human prostate epithelial cell line
(RWPE-1) had been malignantly transformed by chronic low-level arsenic to help determine
whether arsenic affects prostate tumor progression. Control and CAsE-PE (chronic-arsenic–exposed
human prostate epithelial) cells were continuously maintained in a complete medium [keratinocyte
serum-free medium (K-SFM) with bovine pituitary extract and epidermal growth factor] or in a
steroid-depleted medium (K-SFM alone). The arsenic-transformed cells showed a more rapid prolif-
eration rate in complete medium than did control cells and also showed sustained proliferation in
steroid-reduced medium. Although both control and CAsE-PE cells showed similar levels of andro-
gen receptor (AR), androgens were less effective in stimulating cell proliferation and AR-related gene
expression in CAsE-PE cells. For instance, dihydrotestosterone caused a 4.5-fold increase in prostate-
speciﬁc antigen transcript in control cells but only a 1.5-fold increase in CAsE-PE cells. CAsE-PE
cells also showed relatively low levels of growth stimulation by nonandrogen steroids, such as estra-
diol. Thus, arsenic-induced malignant transformation is associated with acquired androgen indepen-
dence in human prostate cells. This acquired androgen independence was apparently not due to AR
up-regulation, increased activity, or altered ligand speciﬁcity. The precise manner in which arsenic
altered CAsE-PE growth and progression is undeﬁned but may involve a bypass of AR involving
direct stimulation of downstream signaling pathways. Key words: androgen independent, AR,
arsenic, cancer progression, malignant transformation, prostate. Environ Health Perspect
113:1134–1139 (2005). doi:10.1289/ehp.7832 available via http://dx.doi.org/ [Online 5 May 2005]This aromatase is expressed in the human
prostate, suggesting a local role for estrogen.
Indeed, estrogen can elicit direct actions
affecting the growth of prostate cells and can
affect estrogen receptor (ER)-mediated gene
transcription (Curtis et al. 1997; Robertson
et al. 1996). Estrogens have been implicated in
the promotion of aberrant prostate growth
(Farnsworth 1999) and do not necessarily
always work through indirect inhibition of
androgen pathways (Harkonen and Makela
2004). In animal models, it has been well estab-
lished that estrogen may play an important role
in prostate carcinogenesis (Bosland 2000). As in
other tissues, the effects of estrogen on the
prostate are likely transduced primarily by ERs.
Prostate cells can be a direct target of estrogen
regulation, because they contain both ER-α
and ER-β (Harkonen and Makela 2004).
Recent evidence indicates that antiestrogens can
perturb prostate cancer formation and progres-
sion and that this effect is at the level of the ER
within prostate cells (Harkonen and Makela
2004; Raghow et al. 2002).
In the present study, we used a model sys-
tem in which chronic arsenic exposure
induced malignant transformation of the
human prostate epithelial cell line RWPE-1
(Achanzar et al. 2002) in order to help deﬁne
the role of arsenic in prostate cancer progres-
sion. These transformed CAsE-PE cells rapidly
produce very aggressive prostate carcinoma-
like tumors upon inoculation into nude mice
that overexpress prostate-specific antigen
(PSA) while maintaining epithelial characteris-
tics (Achanzar et al. 2002). Specifically, we
tested the hypothesis that arsenic may induce
androgen-independent growth of human
prostate epithelial cells. Our data show that
there is loss of androgen dependence after
chronic arsenic exposure and the simultaneous
acquisition of an aggressive growth behavior.
AR expression or ligand specificity played a
minimal role in this arsenic-induced prostate
cancer cell progression.
Materials and Methods
Chemicals and reagents. We purchased sodium
arsenite (NaAsO2; purity, 96.6%) from Sigma
Chemical Co. (St. Louis, MO) and keratino-
cyte serum-free medium (K-SFM), EGF,
bovine pituitary extract (BPE), 100× antibiotic-
antimycotic mixture, and TRIzol reagent from
Life Technologies, Inc. (Grand Island, NY).
The mouse monoclonal anti-ER-α, the rabbit
polyclonal anti-ER-β, and the mouse mono-
clonal antiactin were purchased from Oncogene
Research Products (Cambridge, MA). We pur-
chased the rabbit polyclonal anti-AR from
Affinity BioReagents (Golden, CO); horse-
radish peroxidase–conjugated secondary anti-
body from Amersham (Piscataway, NJ); and
the Quick Start Bradford protein assay from
Bio-Rad Laboratories (Hercules, CA).
Cells and cell culture. Control (untrans-
formed) RWPE-1 cells were originally derived
from normal human prostate epithelial cells
and are immortalized but nontumorigenic
(Bello et al. 1997; Webber et al. 1997). Unless
otherwise noted, cells were grown in K-SFM
containing 50 µg/mL BPE and 5 ng/mL EGF,
supplemented with 1% antibiotic/antimycotic
mixture. K-SFM containing BPE and EGF is
henceforth termed “complete medium.”
Cultures were incubated at 37°C in a humidi-
ﬁed atmosphere containing 5% CO2 and pas-
saged weekly. Cells were exposed continuously
to 5 µM arsenite (as NaAsO2). The arsenic-
exposed cells were designated chronic-arsenic–
exposed prostate epithelial (CAsE-PE) cells to
distinguish them from the parental RWPE-1
control cells. Parallel cultures grown in arsenic-
free medium provided passage-matched con-
trols. After 29 weeks of exposure, CAsE-PE
cells produced malignant tumors when inocu-
lated into nude mice (Achanzar et al. 2002).
To establish persistence of the observed
changes, cells that had been treated for
30 weeks with arsenic were grown in arsenic-
free medium for an additional 6 weeks. The
phenotypic changes observed in CAsE-PE cells
were stable during this period.
Cell growth rate and the effects of steroids.
To determine the rate of cellular growth, nor-
mal and transformed prostate epithelial cells
were seeded at a density of 3.2 × 103 cells/cm2
in six-well culture plates, and cell proliferation
was determined by cell counting as previously
described (Igawa et al. 2002). After 3 days, one
set of cells was harvested and counted at time 0
with a Z1 model Coulter counter (Coulter
Corporation, Miami, FL). The remaining cells
were provided with fresh complete medium,
and total cell number was determined at various
times thereafter. Fresh complete medium was
added to the cells every 2 days. Steroid-reduced
medium was K-SFM without BPE and EGF.
The BPE is likely the major source of steroids
in complete medium. To determine the effect
of steroid depletion on cell proliferation, cells
were exposed to steroid-depleted medium for
2 days, harvested, and counted at time 0.
Additional cells were counted on days 3, 6,
and 10. Fresh medium was added at each time
point. To determine the effects of exogenous
androgen or estradiol (E2) effects, cells were
seeded at a density of 4 × 103 cells/cm2 and
maintained in regular culture medium for
3 days. Cells were then fed with the steroid-
reduced medium and cultured for an addi-
tional 48 hr before addition of DHT (0.1 µM)
or E2 (1 µM; both from Sigma). In a separate
series of experiments to test the effects of AR
blockade on cell growth, control and CAsE-PE
cells were grown in steroid-depleted media for
48 hr then fed fresh steroid-depleted media
with or without the antiandrogen flutamide
(5µg/mL; Sigma) in the absense or presence of
DHT (0.1µM). Cell proliferation was then
determined after an additional 4 days. Cells
were harvested at various time periods after
treatment, and cell numbers were determined.
RNA extraction and RT-PCR. Total RNA
was isolated using TRIzol reagent by manufac-
turer’s instructions. Reverse transcription–
polymerase chain reaction (RT-PCR) was
performed using a TITANIUM one-step
RT-PCR kit (Clontech, San Jose, CA) and a
GeneAmp PCR system 9700 (Applied
Biosystems, Foster City, CA) according to the
kit’s instructions. Amplification conditions
were as follows: 60 min at 50°C and 5 min at
94°C followed by 35 cycles for 1 sec at 94°C,
1 sec at 55°C (ER-α), 58°C (ER-β), 50°C
(5α-A and 5α-R), or 54°C (PSA), 1 min at
72°C; 1 µg total RNA was used in each ampli-
fication. Primers were designed for ER-α,
ER-β, 5α-A, 5α-R, PSA, and β-actin and were
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Figure 1. Growth rates of control (RWPE-1) and CAsE-PE cells in complete (A) and steroid-reduced (B)
medium. Cells were seeded and maintained as described in “Materials and Methods.” The total cell num-
ber was counted on days 2, 4, and 6 for cells grown in complete culture medium (A) or on days 3, 6, and 10
in steroid-reduced medium (B). The data shown are the means of triplicate wells after normalization to
day 0, indicating cell growth (n = 3); error bars represent SE.
*Signiﬁcantly different from control at the same time point.synthesized by Invitrogen (Grand Island, NY)
as follows: ER-α (5´-TACTGCATCAGATC-
CAAGGG-3´ and 5´-ATCAATGGTGC-
ACTGGTTGG-3´), product size: 650 bp;
ERβ (5´-TGAAAAGGAAGGTTAGTGG-
GAACC-3´ and 3´-TGGTCAGGGACAT-
CATCATGG-5´), product size: 530 bp; 5α-A
(5´-ATACCAGGTCCTGGCTACTG-3´
and 5´-TTGTTGTTAAATATGATGCC-3´),
product size: 273 bp; 5α-R1 (5´-AGCAGAT-
ACTTGAGCCA-3´ and 5´-CCAAAATAGT-
TGGCTGC-3´), product size: 209 bp; 5α-R2
(5´-ACATTACTTCCACAGGACATTT-3´
and 5´-AGGAAATTGGCTCCAGA-3´),
product size: 318 bp; PSA (5´-GAGGTCCA-
CACACTGAAGTT-3´ and 5´-CCTCCT-
GAAGAATCGATTCCT-3´), product size:
214 bp; β-actin (5´-AGAGATGGCCACG-
GCTGCTT-3´ and 5´-ATTTGCGGTG-
GACGATGGAG-3´), product size: 460 bp.
PCR products were electrophoresed on 1.7%
agarose gels, and the gel image was captured
and quantiﬁed with a Gel Doc 2000 System
equipped with TDS Quantity One software
(Bio-Rad). The level of β-actin was used to
normalize results.
Western blot analysis. Total proteins were
isolated using M-PER reagent (Pierce,
Rockford, IL) as directed by the manufacturer.
Protein concentration was determined using
the Bradford assay, and 20–40 µg of each sam-
ple was electrophoresed on NuPage 4–12%
Bis-Tris gels (200V, 30 min) and transferred to
nitrocellulose membranes according to
the manufacturer’s directions (Invitrogen).
Immunoblotting was performed using the
ER-α antibody at a 1:100 dilution, horseradish
peroxidase–conjugated anti-mouse secondary
antibody at a 1:5,000 dilution, ER-β antibody
at a 1:1,000 dilution, AR antibody at a 1:100
dilution, or horseradish peroxidase–conjugated
anti-rabbit secondary antibody at a 1:5,000
dilution, and SuperSignal West Pico chemilu-
minescent substrate (Pierce). Signals were visu-
alized by exposure to Hyperﬁlm (Amersham).
Densitometric analysis was performed using
Quantity One software (Bio-Rad). AR levels
were assessed with and without treatment with
the nonmetabolizable androgen mibolerone
(5 nM, 6 days; Sigma).
Statistical analysis. All data are repre-
sented as mean ± SE derived from three or
more independent experiments. Statistical sig-
niﬁcance of the results was determined by the
Student’s t-test or analysis of variance fol-
lowed by Dunnett’s t-test as appropriate, with
p ≤ 0.05 considered statistically signiﬁcant.
Results
Impact of arsenic-induced malignant transfor-
mation on cellular proliferation. Arsenic can
induce malignant transformation of the human
prostate epithelial cell line RWPE-1, such that
the transformed CAsE-PE cell line produces
aggressive tumors remarkably resembling
prostate carcinoma upon inoculation into nude
mice (Achanzar et al. 2002). Because androgen
independence is often associated with advanced
prostate cancers, we examined the growth of
control and arsenic-transformed prostate
epithelial cells in complete or steroid-reduced
medium. In complete medium, the trans-
formed CAsE-PE cells proliferated approxi-
mately twice as fast as control cells (Figure 1A),
in keeping with their malignant behavior. In a
steroid-reduced medium (K-SFM medium
without steroid-containing BPE complement
or EGF), the growth rate of both cell lines
decreased (Figure 1B). However, CAsE-PE cells
still had a much more rapid growth rate in
steroid-depleted medium, with a doubling time
approximately 2.5-fold higher than control
cells. Thus, the transformed CAsE-PE cells
showed a more rapid growth than did control
cells, which was at least partially independent of
exogenous steroids. This is consistent with
androgen independence in CAsE-PE cells.
Among many possible mechanisms, there
are four ways by which androgen indepen-
dence is attained in prostate cancers through
modification of the AR status or function:
a) overexpression of functional AR, b)A R
mutation resulting in hyper-responsiveness to
androgens, c) activation by nonandrogens
(loss of ligand speciﬁcity), or d) activation of
ligand-independent AR signaling pathways
(Deutsch et al. 2004). Thus, experiments
were designed to test these possibilities.
AR expression, responsiveness, and activ-
ity. To determine whether the androgen-
independent growth in CAsE-PE cells was
dictated by overexpression of AR, we con-
ducted AR expression analysis. As shown in
Figure 2, AR protein in both control and
CAsE-PE cells was expressed at the same
level. Thus, overexpression was clearly not
required for the apparent steroid-independent
growth in CAsE-PE cells. Other studies have
shown that androgens can increase AR levels
via up-regulation of AR (Yeap et al. 1999).
To help test AR responsiveness in control and
CAsE-PE cells, mibolerone, a nonmetabo-
lizable androgen, was used to induce AR
expression. Mibolerone produced a 2.6-fold
increase in the AR protein level in control
cells but increased AR in CAsE-PE cells to a
signiﬁcantly lesser extent (Figure 2).
DHT is known to stimulate gene expres-
sion and prostate cell growth through AR.
When DHT was added to cells growing in
reduced steroid medium, both control and
CAsE-PE cells exhibited growth stimulation
(Figure 3A). However, the growth of control
Benbrahim-Tallaa et al.
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Figure 2. Basal and mibolerone-induced AR protein
expression in control (RWPE-1) and CAsE-PE cells
assessed by Western blot analysis. Cells were
grown in complete medium, and mibolerone (5 nM)
was added 6 days before assessment. Densitometric
data normalized to β-actin are given as fold increase
over control and are expressed as means (n = 3);
error bars represent SE.
*Significantly different from untreated cell-line–matched
cells. **Significantly different from control cells treated
with mibolerone.
Figure 3. Effect of DHT on the growth of control and CAsE-PE cells. (A) Cells were plated in the presence
of 0.1 µM DHT, harvested at 7 days, and counted; growth stimulation by DHT was normalized to the control
cells (set as 1.0). (B) Time course of growth stimulation of normal and arsenic-transformed prostate
epithelial cells by 0.1 µM DHT; the total cell numbers were counted on days 3, 6, and 10. Densitometric
data are given as fold increase over control and are expressed as means (n = 3); error bars represent SE. 
*Signiﬁcantly different from untreated, cell-line–matched cells. **Signiﬁcantly different from control cells treated with DHT.
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**cells was stimulated nearly 2-fold by DHT at
optimal levels (0.1 µM), whereas arsenic-
transformed CAsE-PE cells showed signifi-
cantly less growth stimulation (Figure 3A).
The time course for DHT stimulation of cellu-
lar growth of control and CAsE-PE cells clearly
shows the diminished response in CAsE-PE
cells (Figure 3B). The growth of control cells
on day 10 was stimulated by DHT approxi-
mately 3.5-fold, whereas the growth of
CAsE-PE cells was increased only about 2-fold
compared with cells grown in steroid-depleted
medium. Thus, arsenic-induced malignant
transformation actually appears to confer a
diminished responsiveness of AR.
To further assess the activity of AR in
these cells, we examined androgen-induced
gene expression through AR stimulation. In
this case, we examined PSA expression, which
is activated by androgens through AR. As is
typical with prostate malignancies, CAsE-PE
cells expressed signiﬁcantly more PSA than did
control cells (Figure 4). However, a marked
4.6-fold increase in cellular PSA occurred with
DHT treatment in control cells, whereas levels
increased only 23% in CAsE-PE cells. Indeed,
DHT-induced increases in PSA were to a sig-
nificantly lower maximal level in CAsE-PE
cells compared with control cells (Figure 4).
This indicates that stimulation of the AR
pathway by androgen is less effective in pro-
duction of AR-related products in arsenic-
transformed cells. These data, together with
mibolerone data, indicate that the AR in
CAsE-PE cells is actually less responsive, and
argue against an AR mutation that causes AR
hypersensitivity to androgens in these cells.
Impact of antiandrogens on cell prolifera-
tion. Because androgen-independent prostate
cancers often become resistant to antiandrogens
and AR mutations can result in stimulation by
other steroids, including antiandrogens, we
tested the effect of the antiandrogen ﬂutamide
on DHT-stimulated growth in control and
CAsE-PE cells. DHT-stimulated growth was
completely suppressed by flutamide in con-
trol cells (Figure 5). On the other hand, in
CAsE-PE cells, the androgen-stimulated growth
was blocked only partially by ﬂutamide.
Collectively, CAsE-PE cells responded dif-
ferently to DHT, ﬂutamide, or mibolerone, all
of which are thought to act through the AR.
In light of the ﬁndings that AR levels are simi-
lar, the androgen-independent growth compo-
nent of CAsE-PE cells does not appear to be
due to overexpression of a functional AR, or
through an AR modiﬁcation that alters steroid
sensitivity or selectivity.
Expression of androgen metabolism
enzymes. It is possible that an aspect of andro-
gen independence in CAsE-PE cells could
involve a more efﬁcient conversion of testos-
terone to DHT by 5α-R. Thus, we evaluated
the expression of 5α-R isoforms in control
and CAsE-PE cells (Figure 6). Both control
and arsenic-transformed CAsE-PE cells
expressed 5α-R1 RNA with an elevated
expression in CAsE-PE cells (~ 53%). 5α-R2
mRNA was not detectable in either control or
CAsE-PE cells (data not shown). The expres-
sion of 5α-A, which produces E2 from testos-
terone, was also assessed in each cell line, and
both cell lines showed a similar expression level.
Effect of E2 on cell proliferation. In many
instances of acquired androgen independence
in prostate cancer, the AR is modified such
that it becomes sensitive to a variety of steroids,
including nonandrogens. To test this hypothe-
sis, we also determined the cellular growth of
control and CAsE-PE cells after exposure to
various concentrations of E2. Both control
and CAsE-PE cells exhibited optimal growth
stimulation by E2 at a concentration of 1 µM
(Figure 7A). However, the growth of control
cells on day 7 was stimulated by 1.8-fold,
whereas the growth of CAsE-PE cells was
stimulated only about 1.2-fold. We subse-
quently determined the time course of cellular
growth of control and CAsE-PE cells after
exposure to 1 µM E2. As shown in Figure 7B,
the growth of control cells on day 10 was
stimulated by approximately 3-fold, whereas
the growth of CAsE-PE cells was increased
only about 1.3-fold. Growth of control cells is
significantly stimulated by physiologic con-
centrations of E2; this growth increase appears
to be comparable with that induced by DHT.
In contrast, the E2 growth-stimulating effect
in CAsE-PE cells is signiﬁcantly less than that
observed in control cells.
We also studied the expression of ERs.
ER-α and ER-β transcripts occurred in both
control and CAsE-PE cells (Figure 8A). ER-α
was down-regulated in CAsE-PE cells com-
pared with control cells (~ 50%, p < 0.05).
ER-β mRNA levels are distinctly lower in both
cell lines compared with ER-α. Nevertheless,
ER-β expression was increased in CAsE-PE
cells compared with control cells (1.6-fold,
p = 0.05). ER-α and ER-β proteins were
expressed in both control and CAsE-PE cells
and were consistent with the data on mRNA
(Figure 8B).
Arsenic-induced androgen independence
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Figure 4. Androgen effects on PSA expression of
control (RWPE-1) and CAsE-PE cells. RNA was iso-
lated and subjected to RT-PCR analysis using a set
of primers designed to amplify PSA and β-actin
gene products after DHT treatment. See “Material
and Methods” for details. 
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Figure 5. The effect of flutamide on the growth of
control (RWPE-1) and CAsE-PE cells. Control and
CAsE-PE were exposed to ﬂutamide in the presence
or absence of DHT. Data are expressed as means
(n = 3); error bars represent SE. 
*Significantly different from untreated, cell-line–matched
cells. **Significantly different from control cells treated
with DHT or DHT plus ﬂutamide.
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analysis normalized to β-actin. Data are expressed
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The results demonstrate that inorganic arsenic
can potentially affect prostate cancer progres-
sion. In this regard, a clear transition from the
androgen-sensitive to androgen-independent
state occurs during arsenic-induced malignant
transformation of human prostate epithelial
cells. The androgen response program is critical
to the progression of human prostate cancer
(Feldman and Feldman 2001). Prostate cancer
initially requires androgen for growth and
responds to hormone ablation therapies
(Feldman and Feldman 2001). However, the
disease often progresses to a state of reduced
hormone dependence, which is commonly
fatal (Arnold and Isaacs 2002). Several mecha-
nisms may contribute to the progression of
prostate cancer to an androgen-independent
state (Grossmann et al. 2001). AR ampliﬁca-
tion is found in approximately 30% of clinically
advanced prostate cancer cases (Koivisto et al.
1997; Visakorpi et al. 1995). Overexpression
of transcriptional coactivators also accompa-
nies progression in some cases and facilitates
the activity of AR (Comuzzi et al. 2003).
Mutations in the AR may allow it to respond
to different steroids as well as antiandrogens
(Taplin et al. 1999). However, arsenic-induced
androgen independence in CAsE-PE cells is
not associated with AR overexpression or
altered AR ligand specificity, indicating that
arsenic affects progression through a non-AR-
dependent mechanism. In this regard, the
growth factors and receptors associated with
prostate cancer progression often regulate cell
growth through stimulation of Ras signaling
pathways (Weber and Gioeli 2004). Recent
data from our laboratory indicate that wild-
type k-ras activation is strongly correlated with
arsenic-induced transformation in CAsE-PE
cells (Benbrahim-Tallaa et al., in press).
Chronic activation of ras by autocrine and
paracrine growth factor stimulation is thought
to be a common mechanism for prostate can-
cer progression, and attenuation of ras signal-
ing can restore androgen sensitivity to
hormone-refractory prostate cancer cells (Bakin
et al. 2003a, 2003b). Because arsenic-induced
androgen independence does not appear to
involve AR overexpression or altered ligand
specificity, a bypass of AR through chronic
overexpression of Ras may well contribute to
this progression. Further research on arsenic
stimulation of this important growth signaling
pathway is ongoing.
The role of ER in prostate cancer progres-
sion is not completely understood. In the pre-
sent study, ER-α expression was signiﬁcantly
reduced in arsenic-transformed CAsE-PE cells.
ER-α expression is often down-regulated in
prostate cancer (Linja et al. 2003) and is associ-
ated with a poor prognosis because it reduces
the effectiveness of endocrine therapy (Konishi
et al. 1993). Thus, the reduced ER-α expression
in arsenic-transformed CAsE-PE cells may indi-
cate a more advanced tumor cell, consistent
with the production of invasive carcinoma
when these cells are inoculated into nude mice
(Achanzar et al. 2002). ER-β expression may be
reduced in primary prostate cancers, but its
expression returns in metastases (Weihua et al.
2002). In fact, recent studies have shown that
ER-β is the predominant ER subtype expressed
in prostate cancer metastases (Lai et al. 2004;
Leav et al. 2001). Therefore, the overexpression
of ER-β in CAsE-PE cells may also suggest a
more progressed state.
Both control and CAsE-PE cells expressed
only the type 1 isoform of 5α-R in the present
study. This is consistent with the androgen-
independent prostate tumor cell lines DU-145
and PC3 (Delos et al. 1995; Negri-Cesi et al.
1999) and isolated human prostate cancer
epithelial cells (Delos et al. 1995) where only
5α-R1 is detected. Generally speaking, 5α-R1
appears to predominate in cancerous prostate
tissue (Occhiato et al. 2004) and is highly
overexpressed in a subset of prostate cancers
but not highly expressed in benign prostatic
hyperplasia (Thomas et al. 2003). The overex-
pression of 5α-R1 in arsenic-transformed
CAsE-PE cells indicates that it is possible that
these cells could convert more testosterone to
DHT. However, 5α-R1 overexpression does
not appear to be involved in aberrant cell pro-
liferation in DU-145 cells, because a speciﬁc
5α-R1 inhibitor (LY306089), which blocks
DHT formation, has no effect on proliferation
of DU-145 cells (Kaefer et al. 1996). Thus,
5α-R1 overexpression does not appear to
account for the hyperproliferation observed
for arsenic-transformed CAsE-PE cells.
The low levels of 5α-A transcript in control
and CAsE-PE cells indicate that the intracellular
Benbrahim-Tallaa et al.
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Figure 7. Effect of E2 on the growth of control (RWPE-1) and CAsE-PE cells plated in the presence of 1 µM
E2, harvested at 7 days, and counted. (A) Growth stimulation by E2 normalized to the control cells (set as
1.0). (B) Time course of growth stimulation of normal and arsenic-transformed prostate epithelial cells by
1µ M  E 2. Total cell numbers were counted on days 3, 6, and 10; the data shown are the means and SEs of
triplicates. Similar results were found in two independent experiments. Densitometric data are given as
fold increase over control and are expressed as means (n = 3); error bars represent SE.
*Signiﬁcantly different from untreated cell-line–matched cells. **Signiﬁcantly different from control cells treated with E2.
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Figure 8. Expression of ERs in control (RWPE-1) and CAsE-PE cells. (A) RNA was isolated and subjected to
RT-PCR analysis using a set of primers designed to amplify ER-α, ER-β, and β-actin gene products.
(B) Proteins were isolated and separated and subjected to Western blot analysis monoclonal anti-ER-α,
polyclonal anti-ER-β, and monoclonal antiactin. Densitometric data are normalized to β-actin and
expressed as means (n = 3); error bars represent SE.
*Signiﬁcantly different from control cells.Arsenic-induced androgen independence
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production of estrogens is not a characteristic of
these cells and limits the possibility that testos-
terone, through estrogen formation, might still
indirectly be active in CAsE-PE cells. 5α-A is
observed in normal and pathologic prostate
specimens (Matzkin and Soloway 1992) and in
prostate cancer cells (Block et al. 1996).
However, the poor response to E2 and the very
weak expression of aromatase in androgen-
independent CAsE-PE cells indicates local
aromatization of testosterone probably does
not play a major role in arsenic-induced
prostate cancer progression.
In summary, the present results clearly
show that arsenic can precipitate events leading
to rapid growth and greatly reduce androgen
dependence during malignant transformation
of human prostate epithelial cells. Arsenic-
induced acquisition of androgen independence
does not involve overexpression of AR or any
apparent changes in AR ligand sensitivity.
Changes in androgen metabolism, estrogen
production, or ER levels and sensitivity also
appear to have limited roles in this conversion.
However, the fact that a common contaminant
of the human environment can potentially
affect prostate cancer progression provides
strong incentive to further define the role of
arsenic in prostate cancer progression.
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